Safe Harbor Signs Non-Binding Term Sheet to Hand 85% of Combined Company to Opifex Media
SHFS sits 85% above its 52-week low of $0.073 on elevated volume (6.9× avg).
Summary
Safe Harbor signed a non-binding term sheet for Opifex Media to become a wholly owned subsidiary, with Opifex holders owning 85% of the combined company and Safe Harbor holders 15%. The same filing discloses 23.9 million shares issued on Series B conversions, leaving 24.9 million shares outstanding.
Updates
· Reuters — Combined company would remain listed on Nasdaq under a new name, with Greg Newman as Chairman.
Key Events · M&A and Partnerships · SHFS
-
Non-Binding Opifex Term Sheet Signed
Opifex Media Inc., a Beverly Hills creator-economy holding company, would merge into a wholly owned Safe Harbor subsidiary and be accounted for as a reverse acquisition; the term sheet is non-binding except for exclusivity and confidentiality.
-
Existing Holders Left With 15%
Opifex security holders would own 85% and Safe Harbor stakeholders 15% of the combined company on a fully diluted basis, adjustable to a 12.5%-17.5% Safe Harbor range based on an independent fairness opinion; Opifex valuation contemplated at not less than $50 million.
-
Series B Conversions Cross 5% Threshold
23,914,988 common shares were issued on conversion of 6,545 Series B preferred shares from July 1 to October 23, 2026 at an average $0.2737, with the conversion price now $0.1210; 24,942,735 shares were outstanding as of October 23, 2026 and no cash was received.
-
Closing Targeted Before April 19, 2027
Closing requires a definitive agreement, Opifex audited financials, Series B consents, stockholder and Nasdaq approvals, and any required financing; a 45-day exclusivity period applies and the combined company must meet Nasdaq listing standards at closing, potentially via a registered equity financing, up to $1.0 million of direct investment and a reverse split.
Analysis · SHFS · Finance
A non-binding term sheet is not a deal, but the proposed structure would leave existing Safe Harbor holders with only 15% of the combined company (adjustable to 12.5%-17.5%), while Opifex designates the officers and four of five board seats. Effectively a reverse acquisition dressed as a merger, it is the company's chosen route out of its Nasdaq bid-price problem after receiving a second compliance period through April 19, 2027. Nothing is signed: the term sheet is non-binding, Opifex still owes audited financials and a valuation of at least $50 million, Series B holders must consent to converting at closing, and a registered equity financing may be needed to satisfy listing standards. Separately, the 8-K discloses that Series B conversions crossed the 5% threshold, issuing 23,914,988 shares at an average $0.2737 with the conversion price now reset to $0.1210 — heavy dilution against 24,942,735 shares outstanding as of October 23, 2026.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 45.6% of the 241 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SHFS was trading at $0.13 on NASDAQ in the Finance sector, with a market capitalization of approximately $136.1K. The 52-week trading range was $0.07 to $42.28. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.